A 52-week study offered insight into the effectiveness and safety of dupilumab in adult patients with treatment-refractory atopic dermatitis.
Learn more at the Journal of the American Academy of Dermatology.
Long-term effectiveness of Dupilumab in treatment-refractory atopic dermatitis patients
